Shanghai RAAS Blood Products Co Ltd Class A (002252) — Net Asset Quality Index
Shanghai RAAS Blood Products Co Ltd Class A (002252) has a Net Asset Quality Index of 85.6% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥37.98 Billion minus total liabilities of CN¥5.46 Billion yields net assets of CN¥32.52 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Read 002252 liabilities breakdown for a breakdown of total debt and financial obligations.
Quality Index
Net Assets
Total Assets
Total Liabilities
Shanghai RAAS Blood Products Co Ltd Class A Net Asset Quality Index Over Time (2005–2025)
This chart shows how Shanghai RAAS Blood Products Co Ltd Class A's Net Asset Quality Index has evolved across 21 annual periods from 2005 to 2025. As of March 2026, the index stands at 85.6%, representing net assets of CN¥32.52 Billion against total assets of CN¥37.98 Billion CNY. For live market cap and overall valuation, see Shanghai RAAS Blood Products Co Ltd Clas (002252) total market value.
Annual Net Asset Quality Index for Shanghai RAAS Blood Products Co Ltd Class A (2005–2025)
The table below presents the year-by-year Net Asset Quality Index for Shanghai RAAS Blood Products Co Ltd Class A from 2005 to 2025, covering 21 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. Check 002252 strategic asset allocation to assess the company's strategic physical and investment asset allocation.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 85.9% | CN¥32.47 Billion | CN¥37.80 Billion | CN¥5.34 Billion | ▼ -9.1 pp |
| 2024 | 95.0% | CN¥31.94 Billion | CN¥33.63 Billion | CN¥1.69 Billion | ▲ +2.1 pp |
| 2023 | 92.9% | CN¥29.65 Billion | CN¥31.93 Billion | CN¥2.28 Billion | ▼ -1.7 pp |
| 2022 | 94.6% | CN¥28.81 Billion | CN¥30.46 Billion | CN¥1.64 Billion | ▼ -0.5 pp |
| 2021 | 95.1% | CN¥25.90 Billion | CN¥27.24 Billion | CN¥1.33 Billion | ▼ -3.5 pp |
| 2020 | 98.6% | CN¥25.13 Billion | CN¥25.49 Billion | CN¥363.74 Million | ▲ +1.6 pp |
| 2019 | 96.9% | CN¥11.49 Billion | CN¥11.85 Billion | CN¥361.95 Million | ▲ +1.3 pp |
| 2018 | 95.6% | CN¥10.90 Billion | CN¥11.40 Billion | CN¥496.56 Million | ▲ +9.3 pp |
| 2017 | 86.3% | CN¥12.48 Billion | CN¥14.46 Billion | CN¥1.98 Billion | ▼ -2.4 pp |
| 2016 | 88.7% | CN¥11.73 Billion | CN¥13.23 Billion | CN¥1.50 Billion | ▼ -4.0 pp |
| 2015 | 92.7% | CN¥10.71 Billion | CN¥11.56 Billion | CN¥843.64 Million | ▲ +0.8 pp |
| 2014 | 91.9% | CN¥8.62 Billion | CN¥9.38 Billion | CN¥755.16 Million | ▲ +22.0 pp |
| 2013 | 69.9% | CN¥1.10 Billion | CN¥1.58 Billion | CN¥473.37 Million | ▼ -14.4 pp |
| 2012 | 84.4% | CN¥1.02 Billion | CN¥1.21 Billion | CN¥188.79 Million | ▼ -7.5 pp |
| 2011 | 91.9% | CN¥927.27 Million | CN¥1.01 Billion | CN¥82.26 Million | ▲ +2.5 pp |
| 2010 | 89.3% | CN¥831.21 Million | CN¥930.33 Million | CN¥99.12 Million | ▼ -3.2 pp |
| 2009 | 92.5% | CN¥763.33 Million | CN¥825.22 Million | CN¥61.88 Million | ▲ +1.7 pp |
| 2008 | 90.8% | CN¥754.76 Million | CN¥831.19 Million | CN¥76.42 Million | ▲ +35.3 pp |
| 2007 | 55.5% | CN¥170.01 Million | CN¥306.54 Million | CN¥136.53 Million | ▲ +7.2 pp |
| 2006 | 48.2% | CN¥156.77 Million | CN¥325.16 Million | CN¥168.39 Million | ▼ -21.2 pp |
| 2005 | 69.4% | CN¥231.70 Million | CN¥333.63 Million | CN¥101.93 Million | — |